







Item 8.01. Other Events.

On June 15, 2018, TG Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of an integrated analysis of long term safety data of umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, as well as the first preclinical data presentation of TG-1701, the Company’s orally available and covalently-bound BTK inhibitor, at the 23rd Congress of European Hematology Association (EHA). On June 15, 2018, the Company also announced updated clinical data from its ongoing Phase I study evaluating umbralisib (TGR-1202), the Company's PI3K delta inhibitor in combination with ruxolitinib, the JAK 1/2 inhibitor, in ruxolitinib experienced patients with myelofibrosis (MF), at the 23rd Congress of EHA. Copies of the press releases are being filed as Exhibits 99.1 and Exhibits 99.2 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated June 15, 2018.

99.2 Press Release, dated June 15, 2018.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: June 15, 2018

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer